NRAS and neoplasm: The pyrosequencing analysis of tumor tissue showed that 10 out of 19 (52%) patients had a BRAF mutation, 5 out 19 (26%) harbored a NRAS mutation, and 4 out of 19 (21%) patients were WT for both BRAF and NRAS genes (Table 1).